Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals, Inc. (ARMP) Common Equity (2016 - 2018)

Armata Pharmaceuticals' Common Equity history spans 6 years, with the latest figure at $8.8 million for Q3 2018.

  • For Q3 2018, Common Equity fell 9.85% year-over-year to $8.8 million; the TTM value through Sep 2018 reached $8.8 million, down 9.85%, while the annual FY2017 figure was $24.3 million, 150.37% up from the prior year.
  • Common Equity for Q3 2018 was $8.8 million at Armata Pharmaceuticals, down from $11.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $24.3 million in Q4 2017 and bottomed at -$34.0 million in Q1 2014.
  • The 5-year median for Common Equity is $9.7 million (2016), against an average of $7.0 million.
  • The largest annual shift saw Common Equity surged 389.24% in 2016 before it tumbled 54.1% in 2017.
  • A 5-year view of Common Equity shows it stood at $3.4 million in 2014, then soared by 355.72% to $15.7 million in 2015, then crashed by 37.92% to $9.7 million in 2016, then soared by 150.37% to $24.3 million in 2017, then plummeted by 63.87% to $8.8 million in 2018.
  • Per Business Quant, the three most recent readings for ARMP's Common Equity are $8.8 million (Q3 2018), $11.6 million (Q2 2018), and $14.7 million (Q1 2018).